研究疾病:
|
冠心病稳定型劳力性心绞痛(I、II级)
|
研究疾病代码:
|
|
Target disease:
|
coronary heart disease with stable exertional angina pectoris (Grade I, II)
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
单臂
Single arm
|
研究所处阶段:
Study phase:
|
IV期临床试验
Phase IV clinical trial
|
研究目的:
|
以用药后不良事件发生率等为评价指标,评价三七龙血竭胶囊治疗冠心病稳定型劳力性心绞痛(I、II级)的临床安全性。同时以用药结束时西雅图心绞痛调查量表(SAQ)评分较用药前的变化为主要评价指标,评价三七龙血竭胶囊治疗冠心病稳定型劳力性心绞痛(I、II级)的临床有效性。
|
Objectives of Study:
|
The incidence of adverse events after medication was used as evaluation indicators to evaluate the clinical safety of Sanqi Longxuejie Capsules in the treatment of coronary heart disease with stable exertional angina pectoris (Grade I, II). At the same time, the change in the Seattle Angina Pectoris Survey (SAQ) score at the end of the medication compared with before the medication was used as the main evaluation index to evaluate the clinical effectiveness.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
(1) 18周岁≤年龄≤75周岁成年患者,性别不限;
(2) 符合稳定性劳力型心绞痛西医诊断标准(参考2018《稳定性冠心病诊断与治疗指南》);
(3) 心绞痛分级为Ⅰ、Ⅱ级:Ⅰ级:一般体力活动(如步行和登楼)不受限,但在强、快或持续用力时发生心绞痛;Ⅱ级:一般体力活动轻度受限。快步、饭后、寒冷或刮风中、精神应激或醒后数小时内发作心绞痛。一般情况下平地步行200m以上或登楼一层以上受限;
(4) 中医证型符合心血瘀阻证:①固定性胸痛(4分);②舌质紫暗或舌体有瘀斑瘀点 (4分);③舌下静脉紫 (3分);④面色紫暗 (3分);⑤身体有瘀点或瘀斑 (3分);⑥肢体麻木(3分);⑦口唇紫暗或暗红(2分);⑧脉涩(2分)。得分相加≥8分即可诊断;
(5) 签署知情同意书。
|
Inclusion criteria
|
(1) Adult patients 18 years of age ≤ age ≤ 75 years of age, regardless of gender;
(2) Meet the diagnostic criteria of western medicine for stable labor-induced angina pectoris (refer to the 2018 "Guidelines for the Diagnosis and Treatment of Stable Coronary Heart Disease");
(3) Angina pectoris is classified into grades Ⅰ and Ⅱ: grade Ⅰ: general physical activity (such as walking and climbing stairs) is not restricted, but angina pectoris occurs during strong, rapid or continuous exertion; grade Ⅱ: general physical activity is slightly restricted. Angina pectoris occurs within a few hours after walking fast, after a meal, cold or windy, mentally stressed, or within a few hours after waking up. Under normal circumstances, walking on flat ground for more than 200m or for climbing buildings above one floor is restricted;
(4) TCM syndromes conform to the heart and blood stasis syndrome: ① Fixed chest pain (4 points); ② Dark purple tongue or petechiae on the tongue (4 points); ③ Purple sublingual vein (3 points); ④ Dark purple complexion (3 points); ⑤ petechiae or ecchymosis on the body (3 points); ⑥ numbness of limbs (3 points); ⑦ dark purple or dark red lips (2 points); ⑧ astringent pulse (2 points). The score can be diagnosed by adding ≥8 points;
(5) Sign the informed consent form.
|
排除标准:
|
(1)经检查证实为急性冠脉综合征、重症心肌炎、重度心律失常,重度心功能不全者(心功能Ⅳ级或心脏超声检查左室射血分数(LVEF)<30%)者,以及其他心脏疾病、重度神经官能症、更年期症候群、甲亢、胆心病、胃食管反流等所致胸痛者;
(2)心绞痛分级属III~IV级:III级:一般体力活动明显受限,一般情况下平地步行200m以内,或登楼一层引起心绞痛;Ⅳ级:轻微活动或休息时即可发生心绞痛;
(3)合并高血压控制不良(收缩压≥180mmHg或舒张压≥110mmHg)者;
(4)有活动性出血或有出血高风险者(如在最近3个月内明确诊断有消化性溃疡者);
(5)合并严重肝肾功能损害(ALT、AST或总胆红素>2倍正常参考值上限,或Scr>1.5倍正常参考值上限),合并造血系统等严重原发性疾病、恶性肿瘤、精神病者;
(6)妊娠、计划妊娠或哺乳期妇女;
(7)近3个月内参加其它临床试验者;
(8)对试验药物或其所含成分过敏者;
(9)研究者认为不宜参加本临床试验患者及其他原因不配合、依从性差等患者。
|
Exclusion criteria:
|
(1) Those who have been confirmed as acute coronary syndrome, severe myocarditis, severe arrhythmia, severe cardiac insufficiency (heart function grade IV or left ventricular ejection fraction (LVEF) <30% by echocardiography), and others Patients with chest pain caused by heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, biliary heart disease, gastroesophageal reflux, etc.;
(2) Angina pectoris is classified into Grade III~IV: Grade III: General physical activity is obviously restricted. Under normal circumstances, walking on flat ground within 200m, or walking on the ground floor can cause angina; Grade IV: Angina can occur during light activity or rest;
(3) Patients with poor control of hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg);
(4) Those with active bleeding or high risk of bleeding (such as those with peptic ulcer diagnosed within the last 3 months);
(5) Combined with severe liver and kidney damage (ALT, AST or total bilirubin> 2 times the upper limit of the normal reference value, or Scr> 1.5 times the upper limit of the normal reference value), combined with serious primary diseases such as hematopoietic system, malignant tumors, Mentally ill
(6) Women who are pregnant, planning to become pregnant or breast-feeding;
(7) Participants in other clinical trials within the past 3 months;
(8) Those who are allergic to the test drug or its ingredients;
(9) The investigator believes that it is unsuitable to participate in the clinical trial patients and patients who do not cooperate and have poor compliance due to other reasons.
|
研究实施时间:
Study execute time:
|
从From
2021-12-05
至To
2022-12-30
|
征募观察对象时间:
Recruiting time:
|
从From
2021-11-24
至To
2022-12-30
|